Applied Genetic Technologies Corporation Stock News

Applied Genetic Technologies Corp (AGTC) shares closed today at 1.6% above its 52 week low of $1.84, giving the company a market cap of $81M. The stock is currently down 53.3% year-to-date, down 58.4% over the past 12 months, and down 80.7% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 7.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 183.5% The company's stock price performance over the past 12 months lags the peer average by 130.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Applied Genetic Technologies (NASDAQ:AGTC) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates []

Equities research analysts expect that Applied Genetic Technologies Co. (NASDAQ:AGTC) will post earnings per share of ($0.37) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Applied Genetic Technologies earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.42). Applied Genetic Technologies []

During the last session, Applied Genetic Technologies Corporation (NASDAQ:AGTC)s traded shares were 0.38 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stocks price was $2.44, reflecting an intraday gain of 2.09% or $0.05. The 52-week high for the AGTC share is $9.67, that puts it Should Applied Genetic Technologies Corporation (NASDAQ: AGTC) Revive After A -296.31% Drop From Highs? Read More »

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer.

Applied Genetic Technologies Co. (NASDAQ:AGTC) Equities research analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for Applied Genetic Technologies in a research note issued on Wednesday, November 10th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of ($1.61) for the year, down from their prior []

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sa

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-a

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as

After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems.  The Company recently enrolled six pediatric ach

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-